Alnylam Pharmaceuticals, Inc Stock News

Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.

Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, every...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of he...

Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive phase 3 trial by Regeneron Pharmaceuticals that uses Alnylam's technology. We initiated a position in AppLovin, the only scaled, global advertisement network for gaming properties.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference on Wednesday, Nove...

The volatile sector is seeing greater stability, and these four stocks can profit.

Alnylam Pharmaceuticals, Inc. delivered strong Q3 results, driven by Amvuttra's success in ATTR-CM, with total revenues soaring to $1.25 billion. ALNY's market cap surged to $59B as Amvuttra outperformed rivals, but valuation appears stretched at a forward P/S ratio of ~16x. The pipeline is robust, with promising candidates in cardiovascular, rare disease, and metabolic indications, and a $2.7B...

Alnylam Pharmaceuticals, Inc. ( ALNY ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Pushkal Garg - EVP of Development & Medical Affairs and Chief Research & Dev. Officer Jeffrey Poulton - CFO & Executive VP Conferen...